IP Explained: How does the U.S. patent process work?
By Megan Van Etten | June 24, 2021
Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...
Read More
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
By Cynthia Hicks | May 14, 2021
Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead...
Read More
The Biden Administration allows politics to upend a pragmatic pandemic response
By Megan Van Etten | May 14, 2021
Last week, the Biden Administration announced that it will support a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which...
Read More
IP Explained: Intellectual property system working to combat COVID-19
By Megan Van Etten | May 28, 2020
Biopharmaceutical companies are working around the clock to research and develop COVID-19 vaccines and treatments. Intellectual property (IP) has enabled robust research collaboration among...
Read More
The continued imperative to protect U.S. innovation worldwide
By Chris Moore | April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
By Tom Wilbur | August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...
Read More
IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
